Investigational drug · Phase 2
SPC 2004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension, Essential, Cardiovascular Diseases, Cardiology.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SPC 2004"
First trial start
2024
Jun 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPC 2004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension, Essential
- Cardiovascular Diseases
- Cardiology
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SPC 2004" as an intervention, largest first.
- Efficacy and Safety of SPC1001 in Patients With Essential HypertensionPivotal-lookingRecruiting
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT06826872 · 252 participants (planned) · Start Jun 12, 2024 · Primary completion Oct 8, 2025
Drug: SPC 1001 Mid2; SPC 2002 and 2 more · For: Hypertension, Essential; Cardiovascular Diseases; Cardiology
Sites: Seoul, South Korea
GlaxoSmithKlineGSK (GSK)
NCT01587768 · 1 participants · Start Nov 2011 · Primary completion Jul 2014
Drug: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009 · For: Infections, Bacterial
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension, Essential
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.